Evidence map›Paper›PMID 21643694›Full record

ArticleInternational journal of hematology2011

Successful treatment of Hodgkin lymphoma in second trimester of pregnancy: feasibility of ABVD regimen.

Noriyoshi Iriyama, Akira Horikoshi, Toshitake Tanaka, Yukio Hirabayashi, Hitomi Kodaira, Yoshihiro Hatta, Jin Takeuchi

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Noriyoshi IriyamaDepartment of Internal Medicine, Nihon University School of Medicine, Nerima-Hikarigaoka Hospital, 2-11-1 Hikarigaoka, Nerima-Ku, Tokyo, 179-0072, Japan. iriyama.noriyoshi@nihon-u.ac.jp.
Akira HorikoshiDepartment of Internal Medicine, Nihon University School of Medicine, Nerima-Hikarigaoka Hospital, 2-11-1 Hikarigaoka, Nerima-Ku, Tokyo, 179-0072, Japan.
Toshitake TanakaDepartment of Internal Medicine, Nihon University School of Medicine, Nerima-Hikarigaoka Hospital, 2-11-1 Hikarigaoka, Nerima-Ku, Tokyo, 179-0072, Japan.
Yukio HirabayashiDepartment of Hematology and Rheumatology, Nihon University School of Medicine, Itabashi Hospital, 30-1 Oyaguchi Kami-cho, Itabashi-Ku, Tokyo, 173-8610, Japan.
Hitomi KodairaDepartment of Internal Medicine, Nihon University School of Medicine, Nerima-Hikarigaoka Hospital, 2-11-1 Hikarigaoka, Nerima-Ku, Tokyo, 179-0072, Japan.
Yoshihiro HattaDepartment of Hematology and Rheumatology, Nihon University School of Medicine, Itabashi Hospital, 30-1 Oyaguchi Kami-cho, Itabashi-Ku, Tokyo, 173-8610, Japan.
Jin TakeuchiDepartment of Hematology and Rheumatology, Nihon University School of Medicine, Itabashi Hospital, 30-1 Oyaguchi Kami-cho, Itabashi-Ku, Tokyo, 173-8610, Japan.
Nerima General Hospital · JPNihon University Itabashi Hospital · JPNihon University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 34-year-old woman at 18 weeks of gestation during her third pregnancy was diagnosed with Hodgkin lymphoma stage IVA. She was treated with standard ABVD and showed good response. After three-and-a-half courses of ABVD, she spontaneously delivered a healthy baby girl at 41 weeks of gestation. She continued chemotherapy after delivery. A total of six courses of ABVD were given. Complete remission was obtained and has continued for 6 months post chemotherapy. Neither mother nor child developed any infections during the observation period. The child has also shown no physiological or developmental abnormalities. Here, we describe the feasibility and safety of the ABVD regimen for the treatment of Hodgkin lymphoma, and discuss the optimal treatment strategy.

Indexed as

Pregnancy Trimester, SecondAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinDacarbazineDoxorubicinDrug-Related Side Effects and Adverse ReactionsFemaleHodgkin DiseaseHumansInfant, NewbornPregnancyTreatment OutcomeVinblastineBleomycinDacarbazineDoxorubicinVinblastine

Identifiers

PMID21643694
OpenAlexW2047645489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.